How effective is Rituximab?

Rituximab is a monoclonal antibody that works by targeting the CD20 protein antigen displayed on the B cell surface. It is used to treat a variety of conditions, including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (GAP), and moderate to severe pemphigus.

Rituximab treatment may improve outcomes for someNHL patients. Adding rituximab to standard therapy can enhance patient response to treatment and improve overall outcomes, including extending patient survival without disease progression. Results from three single-arm studies of 296 patients with single-agent therapy for patients with relapsed or refractory, low-grade or follicular CD20positive B cell non-Hodgkin lymphoma Rituximab once-weekly, The median duration of response was 11.2 months for 4 weeks, and rituximab once weekly for 8 weeks for a median duration of 13.4 months.

Rituximab can help improve overall survival in some CLL patients and can also help extend the time patients can live without experiencing disease progression. Adding rituximab to standard treatment can enhance a patient's response to treatment. For previously untreatedCD20positiveCLL combined with fludarabine and cyclophosphamide (FC) Patients, results from a randomized multicenter open-label study of 817 patients, the median progression-free survival 39.8 months. IndiaReliancePharmaceutical retail price50ml:500mg1More than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.